Photo by nci from unsplash
TPS2581Background: Glioblastoma is the most common primary malignant brain tumor with median survival of approximately 15-16 months. Following first recurrence, progression free survival at six mon... Click to show full abstract
TPS2581Background: Glioblastoma is the most common primary malignant brain tumor with median survival of approximately 15-16 months. Following first recurrence, progression free survival at six mon...
Keywords:
first recurrence;
glioblastoma;
pembrolizumab plus;
study pembrolizumab;
phase study
Journal Title: Journal of Clinical Oncology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Oncology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!